Skip to content
Triangle logo TriangleGet started
← Study library

NCT00045305 · REGISTRY CONDITION SEARCH

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2023-06-28

RATIONALE: Photopheresis treats the patient's blood with drugs and ultraviolet light outside the body and kills the white blood cells. Giving photopheresis, pentostatin, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving pentostatin before transplant and cyclosporine or mycophenolate mofetil after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving pentostatin together with photopheresis and total-body irradiation work before donor bone marrow transplant in treating patients with myelodysplastic syndromes.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Complete Response Rate

→

outcome · POSTED

Number of Patients Who Developed Disease Progression After Achieving Complete Response

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Proportion of Graft Versus Host Disease

→

outcome · POSTED

Time to Engraftment for Neutrophil

→

outcome · POSTED

Time to Engraftment for Platelet

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * One of the following cytologically proven myelodysplastic syndromes * Refractory anemia (RA) * RA with ringed sideroblasts * RA with excess blasts * Chronic myelomonocytic leukemia * International Prognosis Scoring System (IPSS) score of at least 0.5 OR red cell transfusion dependence for at least 6 months (2 units per month) * Patients with an IPSS score less than 0.5 may be eligible provided they previously had a higher IPSS score and received chemotherapy at that time * Suitable human leukocyte antigen (HLA)-matched donor (related or unrelated) available * No cord blood donors * Related donors must be genotypically matched (HLA A, B and DR) at 5/6 or 6/6 loci and may be a sibling, parent, or child * Unrelated donors must have high resolution typing done at A, B, C and DR, and must be matched at all or may have a single antigen or allele mismatch at no more than one of these loci * Patients must have \< 20% blasts on bone marrow study within 1 month of study entry * Age of 18 to 70 years * Eastern Cooperative Oncology Group performance status 0-1 * Life expectancy at least 6 months * At least 90 days since prior autologous bone marrow transplantation * Serum erythropoietin level greater than 100 for patients who have not received a prior course of epoetin alfa * No iron deficiency * Iron deficiency anemia treated with iron replacement therapy allowed * Bilirubin less than 2.0 mg/dL * Alkaline phosphatase less than 2 times upper limit of normal (ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 times ULN * Creatinine less than 2.0 mg/dL OR creatinine clearance greater than 50 mL/min * Left ventricular ejection fraction (LVEF) at least 45% by Multigated Acquisition scan (MUGA) or echocardiogram * Carbon Monoxide Diffusing Capacity (DLCO) at least 50% of predicted (corrected for hemoglobin) * Forced expiratory volume in 1 second (FEV\_1) at least 50% of predicted * Recovered from prior chemotherapy * Physically and psychologically capable of undergoing study regimen * Able to receive 600 cGy of total body irradiation * HIV negative * Negative pregnancy test Exclusion Criteria: * Pregnant or nursing * Having other medical condition that would reduce life expectancy * Active ongoing infection * Prior myeloablative or nonmyeloablative allogeneic transplantation for Myelodysplastic syndrome or acute myeloid leukemia
healthy Volunteers
false
maximum Age
70 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Preparative Regimen: Patients underwent photopheresis on two consecutive days and received pentostatin 4 mg/m2/d (total dose = 8 mg/m2) by continuous IV infusion on two consecutive days following photopheresis. Total body irradiation was administered on two consecutive days following pentostatin for a total of 600 cGy given in three 200 cGy fractionated doses. Transplantation: Unmanipulated allogeneic bone marrow or G-CSF mobilized peripheral blood stem cells were infused on day 0 within 48 hours of completion of TBI. Minimum cell dose was 2 ×106 CD34 cells/kg recipient. Acute graft-vs-host-disease (GVHD) prophylaxis: Patients received Cyclosporine or Tacrolimus per institutional preference or protocol beginning no later than day -1. Methotrexate (MTX) was administered on day +1 and +3. Mycofenolate mofetil (MMF) was introduced on day 100 and could be tapered and discontinued after 12 months if no active cGVHD.
    intervention Names
    1. Drug: Cyclosporine
    2. Drug: Methotrexate
    3. Drug: Photopheresis
    4. Drug: Mycofenolate mofetil
    5. Drug: Pentostatin
    6. Procedure: allogeneic bone marrow
    7. Procedure: peripheral blood stem cell
    8. Radiation: Total body irradiation
    label
    Arm I
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm I
    description
    Immunosuppressant
    name
    Cyclosporine
    other Names
    1. Sandimmune®
    2. cyclosporin A
    3. Neoral®Gengraf®
    4. Gengraf®
    5. CSA
    type
    DRUG
  2. arm Group Labels
    1. Arm I
    description
    Antimetabolite
    name
    Methotrexate
    other Names
    1. Methotrexate sodium
    2. MTX
    3. Mexate
    4. Mexate-AQ
    5. Folex
    6. Folex PFS
    7. Abitrexate
    8. Rheumatrex
    9. Amethopterin
    type
    DRUG
  3. arm Group Labels
    1. Arm I
    description
    Psoralens
    name
    Photopheresis
    other Names
    1. 8-methoxypsoralen
    2. Uvadex ®
    3. Methoxsalen
    type
    DRUG
  4. arm Group Labels
    1. Arm I
    description
    an antibiotic with immunosuppressamt properties isolated from Penicillium spp
    name
    Mycofenolate mofetil
    other Names
    1. Cellcept®
    2. RS-61443
    3. mycophenolic acid
    4. Lilly-68618
    5. MMF
    6. Mycophenolate mofetil
    type
    DRUG
  5. arm Group Labels
    1. Arm I
    description
    Purine analogue
    name
    Pentostatin
    other Names
    1. DCF
    2. 2-Deoxycoformycin
    3. Nipent
    type
    DRUG
  6. arm Group Labels
    1. Arm I
    description
    Unmanipulated allogeneic bone marrow
    name
    allogeneic bone marrow
    type
    PROCEDURE
  7. arm Group Labels
    1. Arm I
    description
    G-CSF mobilized peripheral blood stem cell
    name
    peripheral blood stem cell
    type
    PROCEDURE
  8. arm Group Labels
    1. Arm I
    description
    a total of 600 cGy given in 3 200 cGy fractionated doses
    name
    Total body irradiation
    other Names
    1. radiation therapy
    type
    RADIATION
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
17
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Completed response is defined as: Bone marrow evaluation: Repeat bone marrow showing \< 5% myeloblasts with normal maturation of all cell lines, with no evidence for dysplasia (see dysplasia qualifier under peripheral blood evaluation). Peripheral blood evaluation \[absolute values must last at least 2 months\] Hemoglobin \>11 g/dl (untransfused, not on erythropoietin) Neutrophils (1500/mm3 (not on a myeloid growth factor)) Platelets (100,000/mm3 (not on a thrombopoetic agent)) Blasts - 0% No dysplasia. No detectable cytogenetic abnormality, if preexisting abnormality was present
    measure
    Complete Response Rate
    time Frame
    Monthly for the first 3 months from study entry, every 3 months for the first two years from study entry thereafter and then every 6 months for years 3-5.
secondary Outcomes
  1. description
    Disease free survival (DFS) was listed as a secondary endpoint in the study protocol, which would be assessed in patients who achieved complete response (CR). It was defined to be time from CR to documented progression or to death without progression. Patients without documented progression or death reported were censored at the time of last disease evaluation. However, due to the small number of patients with CR, the number of patients who developed disease progression was reported here.
    measure
    Number of Patients Who Developed Disease Progression After Achieving Complete Response
    time Frame
    Monthly for the first 3 months from study entry, every 3 months for the first two years from study entry thereafter and then every 6 months for years 3-5.
  2. description
    Overall survival (OS) is defined to be the time from registration to death from any cause, with follow-up censored at the date of last contact. Kaplan-Meier method was used to estimate the distribution of OS.
    measure
    Overall Survival
    time Frame
    Monthly for the first 3 months from study entry, every 3 months for the first two years from study entry thereafter and then every 6 months for years 3-5.
  3. description
    Proportion of Graft versus Host Disease is calculated as number of patients with Graft versus Host Disease divided by all eligible and treated patients
    measure
    Proportion of Graft Versus Host Disease
    time Frame
    Monthly for the first 3 months from study entry, every 3 months for the first two years from study entry thereafter and then every 6 months for years 3-5.
  4. description
    Time to neutrophil engraftment is defined from date of infusion to date of neutrophil engraftment. Neutrophil engraftment is defined as ANC \> 500/mm3 on two consecutive measurements. The date of engraftment is the date of the first ANC \> 500/mm3.
    measure
    Time to Engraftment for Neutrophil
    time Frame
    Daily while hospitalized and then at least 1x/week for the first 50 days and then at least every other week until day 100.
  5. description
    Time to platelet engraftment is defined from date of infusion to date of platelet engraftment. The platelet engraftment is defined as platelets \> 20,000 on two consecutive measurements, at least seven days apart, without platelet transfusions in between and for at least three days before the first measurement that is over 20,000. The date of engraftment is the date of the first measurement that is over 20,000.
    measure
    Time to Engraftment for Platelet
    time Frame
    Daily while hospitalized and then at least 1x/week for the first 50 days and then at least every other week until day 100.
Full study description
brief Summary
RATIONALE: Photopheresis treats the patient's blood with drugs and ultraviolet light outside the body and kills the white blood cells. Giving photopheresis, pentostatin, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving pentostatin before transplant and cyclosporine or mycophenolate mofetil after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving pentostatin together with photopheresis and total-body irradiation work before donor bone marrow transplant in treating patients with myelodysplastic syndromes.
detailed Description
OBJECTIVES: * Determine the complete response rate in patients with myelodysplastic syndromes treated with reduced-intensity allogeneic bone marrow transplantation, including photopheresis, total body irradiation, and pentostatin. * Determine the disease-free and overall survival of patients treated with this regimen. * Determine the engraftment rate of donor cells in patients treated with this regimen. * Determine the extent and duration of acute and chronic graft-versus-host disease in patients treated with this regimen. * Determine the toxicity of this regimen in these patients. OUTLINE: This is a single-arm, two-stage, multicenter phase II study. * Preparative Regimen: Patients undergo photopheresis using methoxsalen on days -7 and -6 and receive pentostatin intravenously (IV )continuously on days -5 and -4. Total body irradiation is administered on days -3 and -2 for a total of 3 doses. * Transplantation: Allogeneic bone marrow or peripheral blood stem cells are infused on day 0. * Acute graft-vs-host-disease (GVHD) prophylaxis: Patients receive cyclosporine IV on days -1 to 30 and then orally every 12 hours. Cyclosporine dose is then tapered beginning after day 50 and continuing for 6 months in the absence of GVHD. Once cyclosporine dose is significantly decreased, oral mycophenolate mofetil (MMF) is then administered twice a day. MMF dose is then tapered for 12 months in the absence of GVHD. Patients also receive methotrexate IV on days 1 and 3. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 33 patients would be accrued for this study within 2.1 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-41c93bf4860b688d7dbf
      requested nct id
      NCT00045305
      primary nct id
      NCT00045305
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
      payload sha256
      3c908856b853df092afc26be3089b25080d85508712f079cc467469e66c48c15
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-41c93bf4860b688d7dbf
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00045305
      occurrences
      1. context exact
        NCT00045305
        end
        11
        exact text
        NCT00045305
        start
        0
      offset unit
      unicode_code_points
      query cond
      Juvenile Myelomonocytic Leukemia
      query disease state id
      ds-juvenile-myelomonocytic-leukemia
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-juvenile-myelomonocytic-leukemia-000.json
      source file sha256
      cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
      source json pointer
      /studies/104/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      1b1f7d28d3491274ab915b63e249af09b9096a5a31d503f8c4ba9da9efe836c1

    Preserved source evidence · Not medical advice